Screener
Iovance Biotherapeutics, Inc. IOVA Proleukin — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Amtagvi® | $90,721 | $54,074 | $150,943 | $97,645 |
| Proleukin® | 8,592 | 5,878 | 19,800 | 11,631 |
| Total net revenue | $99,313 | $59,952 | $170,743 | $109,276 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s proleukin — revenue?
- Iovance Biotherapeutics, Inc. (IOVA) reported proleukin — revenue of $8.59M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s proleukin — revenue changed year-over-year?
- Iovance Biotherapeutics, Inc.'s proleukin — revenue increased by 46.2% year-over-year, from $5.88M to $8.59M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s proleukin — revenue?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s proleukin — revenue has grown at a 504.7% compound annual growth rate (CAGR), from $1.19M to $43.48M.
- What does proleukin — revenue mean?
- This metric represents the total net revenue generated from the sale of a specific pharmaceutical product or therapeutic asset, excluding any applicable taxes. It serves as a key indicator of the commercial adoption and market demand for the company's established product portfolio. Tracking this revenue stream helps investors evaluate the contribution of specific product lines to the company's overall top-line growth and commercial maturity.
Ask your AI about Iovance Biotherapeutics, Inc.'s proleukin — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude